These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 18991675

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure.
    Fragasso G.
    Int J Clin Pract; 2007 Apr; 61(4):603-10. PubMed ID: 17394434
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of metabolic approach in diabetic patients with coronary artery disease.
    Fragasso G, Salerno A, Spoladore R, Cera M, Montanaro C, Margonato A.
    Curr Pharm Des; 2009 Apr; 15(8):857-62. PubMed ID: 19275650
    [Abstract] [Full Text] [Related]

  • 5. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M.
    Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.
    Fragasso G.
    Card Fail Rev; 2016 May; 2(1):8-13. PubMed ID: 28785448
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modification of myocardial substrate use as a therapy for heart failure.
    Abozguia K, Clarke K, Lee L, Frenneaux M.
    Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
    Willoughby SR, Chirkov YY, Kennedy JA, Murphy GA, Chirkova LP, Horowitz JD.
    Eur J Pharmacol; 1998 Sep 04; 356(2-3):207-13. PubMed ID: 9774251
    [Abstract] [Full Text] [Related]

  • 12. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D.
    Am J Ther; 2011 Nov 04; 18(6):e197-201. PubMed ID: 20393344
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.
    Beadle RM, Williams LK, Kuehl M, Bowater S, Abozguia K, Leyva F, Yousef Z, Wagenmakers AJ, Thies F, Horowitz J, Frenneaux MP.
    JACC Heart Fail; 2015 Mar 04; 3(3):202-11. PubMed ID: 25650370
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ, Mishra S.
    Indian Heart J; 2017 Mar 04; 69(3):393-401. PubMed ID: 28648439
    [Abstract] [Full Text] [Related]

  • 17. Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation.
    Horowitz JD, Chirkov YY.
    Circulation; 2010 Oct 19; 122(16):1547-9. PubMed ID: 20921436
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS, Hill JA.
    Am J Cardiovasc Drugs; 2001 Oct 19; 1(1):23-35. PubMed ID: 14728049
    [Abstract] [Full Text] [Related]

  • 20. The heart metabolism: pathophysiological aspects in ischaemia and heart failure.
    Abozguia K, Shivu GN, Ahmed I, Phan TT, Frenneaux MP.
    Curr Pharm Des; 2009 Oct 19; 15(8):827-35. PubMed ID: 19275646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.